DK1313485T3 - Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion - Google Patents

Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion

Info

Publication number
DK1313485T3
DK1313485T3 DK01964471T DK01964471T DK1313485T3 DK 1313485 T3 DK1313485 T3 DK 1313485T3 DK 01964471 T DK01964471 T DK 01964471T DK 01964471 T DK01964471 T DK 01964471T DK 1313485 T3 DK1313485 T3 DK 1313485T3
Authority
DK
Denmark
Prior art keywords
receptor antagonist
aldosterone receptor
cognitive function
improve cognitive
aldosterone
Prior art date
Application number
DK01964471T
Other languages
Danish (da)
English (en)
Inventor
Kenton N Fedde
Alfonzo T Perez
Joseph F Tooley
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of DK1313485T3 publication Critical patent/DK1313485T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01964471T 2000-08-28 2001-08-28 Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion DK1313485T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22873800P 2000-08-28 2000-08-28

Publications (1)

Publication Number Publication Date
DK1313485T3 true DK1313485T3 (da) 2005-12-27

Family

ID=22858397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01964471T DK1313485T3 (da) 2000-08-28 2001-08-28 Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion

Country Status (10)

Country Link
US (2) US20020111337A1 (fr)
EP (1) EP1313485B1 (fr)
JP (1) JP2004507495A (fr)
AT (1) ATE306272T1 (fr)
AU (1) AU2001285318A1 (fr)
CA (1) CA2419256A1 (fr)
DE (1) DE60114027T2 (fr)
DK (1) DK1313485T3 (fr)
ES (1) ES2251505T3 (fr)
WO (1) WO2002017895A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002366217A1 (en) * 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
JP2005528408A (ja) * 2002-04-26 2005-09-22 シエーリング アクチエンゲゼルシャフト ホルモン補充療法を受けている女性の高血圧治療
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DK1558265T3 (da) * 2002-11-05 2010-03-15 Bayer Schering Pharma Ag Anvendelse af dropspirenon til behandling af hypertension
WO2004060400A1 (fr) * 2003-01-06 2004-07-22 Mitsubishi Pharma Corp Recepteur antipsychotique du facteur de croissance epitheliale a ciblage moleculaire
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
WO2008021666A2 (fr) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Compositions stables de lévétiracétam et procédés
US20090265215A1 (en) * 2008-04-22 2009-10-22 Paul Bernhard Lindstrom Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (fr) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Antagonistes de récepteur de minéralocorticoïde pour le traitement de l'obésité induite par corticoïde
CN103384661B (zh) 2011-01-20 2016-08-10 默沙东公司 盐皮质激素受体拮抗剂
WO2012139495A1 (fr) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de minéralocorticoïdes
US9085568B2 (en) 2011-10-13 2015-07-21 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2013055606A1 (fr) 2011-10-13 2013-04-18 Merck Sharp & Dohme Corp. Antagonistes de récepteur des minéralocorticoïdes
EP2765860B1 (fr) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Antagonistes d'un récepteur des minéralocorticoïdes
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
EP3373920A4 (fr) * 2015-11-13 2019-07-17 Pietro Paolo Sanna Méthodes et compositions pour le traitement de maladies liées à la consommation d'alcool

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133012A (en) * 1961-06-28 1964-05-12 Universal Oil Prod Co Combination catalytic reforming process
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
ES2293944T3 (es) * 1996-12-11 2008-04-01 G.D. Searle Llc. Procedimiento de epoxidacion.
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
BR9915134A (pt) * 1998-11-06 2001-08-07 Searle & Co Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PT1165136E (pt) * 1999-03-05 2004-02-27 Searle Llc Terapia de combinacao de inibidores da enzima de conversao da antagonista da aldosterona epoxi-esteroidal para tratamento de doenca cardiovascular

Also Published As

Publication number Publication date
DE60114027T2 (de) 2006-07-13
DE60114027D1 (de) 2006-02-23
ES2251505T3 (es) 2006-05-01
US20060058274A1 (en) 2006-03-16
AU2001285318A1 (en) 2002-03-13
JP2004507495A (ja) 2004-03-11
US20020111337A1 (en) 2002-08-15
EP1313485B1 (fr) 2005-10-12
WO2002017895A2 (fr) 2002-03-07
ATE306272T1 (de) 2005-10-15
EP1313485A2 (fr) 2003-05-28
WO2002017895A3 (fr) 2003-02-06
CA2419256A1 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
DK1313485T3 (da) Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
MY143366A (en) Muscarinic acetylcholine receptor antagonists
BRPI0510170A (pt) antagonistas do receptor muscarìnico de acetilcolina
MXPA03004832A (es) Compuestos y sus usos.
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
ECSP056254A (es) Antagonistas de receptores muscarínicos de la acetilcolina
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
UY28646A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
UY28645A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
NO20016246L (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
MXPA06000664A (es) Antagonistas del receptor muscarinico de acetilcolina.
TW200519108A (en) Muscarinic acetylcholine receptor antagonists
MXPA05007605A (es) Antagonista del receptor de androgenos.
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
DE60126134D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
DK1146872T3 (da) Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора